BI 1291583: CatC Inhibitor
Phase 2
Indication: non-cystic fibrosis bronchiectasis (nCFBE)
This compound is under investigation, further information will be available soon.
Phase 2
Indication: non-cystic fibrosis bronchiectasis (nCFBE)
This compound is under investigation, further information will be available soon.